About This Meeting:

Chronic liver disease affects more than 1.5 billion people and most commonly results from chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or steatotic liver diseases. Effective treatments exist for viral infections, but effective approaches to alter the course of MASLD are still understudied. MASLD has become a major public health problem because of its high worldwide prevalence of ~30%, its association with serious cardiometabolic abnormalities, and its potential progression to advanced fibrosis/cirrhosis and hepatocellular carcinoma. 

This Keystone Symposia conference on Metabolic Approaches to Chronic Liver Disease will provide the latest data on the molecular and physiological mechanisms that cause hepatic steatosis and its progression to advanced fibrosis, identify key metabolic targets for effective therapeutic intervention, and define the clinical implications of the underappreciated association between sarcopenia and MASLD. The meeting will critically evaluate the role of weight loss and exercise in treating people with MASLD, and present the rationale and results of the most promising early-stage pharmacological interventions. 

The expert speakers represent basic and translational researchers and scientists from industry, whose collective expertise will provide a comprehensive overview of how and why metabolic dysfunction causes MASLD and what interventions offer the best therapeutic opportunities for this increasingly common disease. 

Check out the speaker highlights in the video below: